Lipoprotein News and Research

RSS

A lipoprotein is a biochemical assembly that contains both proteins and lipids. The lipids or their derivatives may be covalently or non-covalently bound to the proteins.

Neptune launches Onemia medical food

Neptune Technologies & Bioressources Inc. enters the pharmaceutical market with the launch of Onemia™, the first medical food of Neptune's subsidiary Acasti Pharma Inc.. Only two years since its foundation, Acasti has completed the development and launch of "Onemia™" on October 21, 2010 at the Cardiometabolic Health Congress meeting in Boston.

25 Oct 2010

Essentialis, FDA enter agreement on SPA for DCCR Phase 3 efficacy study in patients with high triglycerides

Essentialis, Inc. announced today that the company has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase 3 efficacy study required for product registration for its product candidate, Diazoxide Choline Controlled Release Tablet (DCCR), for the treatment of patients with very high triglycerides.

25 Oct 2010

New gene therapy product reduces plasma cholesterol levels

Amsterdam Molecular Therapeutics (AMT) Holding N.V. a leader in the development of gene based therapies, today announced that its gene therapy product incorporating siRNA sequences into microRNA scaffolds to silence Apolipoprotein B100 (AAV-miApoB) was able to significantly lower plasma cholesterol levels in vivo over a period of 18 weeks. These preliminary results suggest that this approach could lead to a treatment for high cholesterol in humans

25 Oct 2010

Study finds metabolic syndrome may indicate breast cancer risk in post-menopausal women

Metabolic syndrome, associated with the sedentary lifestyle and energy dense diet of Western industrialized societies, may be an indicator of breast cancer risk in post-menopausal women, according to a new study to be released at the National Italian American Foundation event, "Let's Talk About It: A Spotlight on Women's Health" on October 22nd at the Washington Hilton in Washington, D.C.

25 Oct 2010

Injecting apoA-V protein may reduce high triglyceride levels: Research

Injecting a protein that helps break down triglycerides may someday help treat an inherited form of high triglycerides, according to a new study in Arteriosclerosis, Thrombosis, and Vascular Biology, an American Heart Association journal.

22 Oct 2010

Study: apoA-V may reduce high triglyceride levels, coronary artery disease

An exciting new study conducted by Children's Hospital Oakland Research Institute scientists identified that an injection of the protein apolipoprotein A-V may reduce high triglyceride levels in the blood and subsequently reduce coronary artery disease. Like cholesterol, elevated levels of triglyceride, a fat in the blood, is associated with the increased risk of heart disease—the number one cause of death in the United States.

22 Oct 2010

Neptune second quarter revenue increases 200% to $4,114,000

Neptune Technologies & Bioressources Inc. today reports its consolidated financial results for the three and six-month periods ended August 31, 2010.

15 Oct 2010

Metabolic screening before conception predicts development of diabetes in subsequent pregnancy

Cardio-metabolic risk factors such as high blood sugar and insulin, and low high density lipoprotein cholesterol that are present before pregnancy, predict whether a woman will develop diabetes during a future pregnancy, according to a Kaiser Permanente study in the current issue of the American Journal of Epidemiology.

13 Oct 2010

Essentialis receives patent for active component in DCCR product

Essentialis, Inc. announced today that the United States Patent & Trademark Office (USPTO) has issued U.S. Patent No. 7,799,777 entitled Salts of potassium ATP channel openers and uses thereof. The patent claims a novel composition of a polymorph of diazoxide choline, the active ingredient in the Essentialis lead product, DCCR. Essentialis has successfully completed phase 2b clinical trials with DCCR, showing a highly significant triglyceride reduction in dyslipidemic patients.

12 Oct 2010

Clinical study data on Natural S-equol supplement presented at NAMS Annual Meeting

Four clinical studies that add to the evidence about the use of a new nutritional supplement containing the whole soy germ-based ingredient Natural S-equol to improve health were presented at the North American Menopause Society (NAMS) Annual Meeting.

8 Oct 2010

Aegerion Pharmaceuticals’ MTP-I Phase III trial published in Atherosclerosis online supplement

ACR Image Metrix, a global imaging contract research organization (CRO) with expertise in imaging trial design, techniques and data extraction, is pleased to announce a Phase III trial, conducted for Aegerion Pharmaceuticals, Inc., was published as an abstract in the online supplement of Atherosclerosis and presented at the 78th European Atherosclerosis Society Congress, which took place June 20-23, 2010, in Hamburg, Germany.

6 Oct 2010

Saturated fat intake has limited impact on CVD risk: Research

For the past three decades, saturated fat has been considered a major culprit of cardiovascular disease (CVD) and as a result dietary advice persists in recommending reduced consumption of this macronutrient. However, new evidence shows that saturated fat intake has only a very limited impact on CVD risk causing many to rethink the "saturated fat is bad" paradigm.

4 Oct 2010

Progenika receives CE Mark approval to market LPLchip in Europe

Progenika Biopharma S.A., a pioneer in the field of personalized medicine, announced today that it has obtained the CE Mark allowing the sale in Europe of its LPLchip(R), the first DNA chip to detect mutations in the lipoprotein lipase (LPL) gene.

27 Sep 2010

Atherotech Diagnostics publishes article on advantages of cholesterol testing

Detailed cholesterol testing for Type 2 diabetes patients is the focus of a newly published article by Atherotech Diagnostics Lab Chief Medical Officer Michael E. Cobble, M.D. The article discusses the clinical advantages of advanced cholesterol testing in reducing cardiovascular disease (CVD) risk in patients with Type 2 diabetes and details several currently available advanced lipid tests, including the VAP® Cholesterol Test from Atherotech.

18 Sep 2010

Researchers find bariatric surgery reduces cardiovascular disease risk

Significant weight loss not only improves daily life of morbidly obese woman but also decreases the risk for cardiovascular disease (CVD). However, many people can not lose weight or can not maintain weight loss without help. Bariatric surgery is emerging as a valuable procedure to help morbidly obese individuals lose weight, as studies have shown; it can improve many health profiles and lower mortality. Now, researchers have found another positive impact of significant weight loss after bariatric surgery, it can significantly improve the lipoprotein profiles of women within a year following surgery.

17 Sep 2010

Gene network behind hardening of arteries, coronary heart disease identified

A gene network behind hardening of the arteries and coronary heart disease has been identified by a team of scientists from Australia, Europe and the United Kingdom. Their findings expose potential targets for the treatment of heart disease.

16 Sep 2010

ABCB4 gene causes bad cholesterol to accumulate in blood: Research

Scientists at the Southwest Foundation for Biomedical Research (SFBR) in San Antonio have found a gene that causes high levels of bad cholesterol to accumulate in the blood as a result of a high-cholesterol diet.

16 Sep 2010

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Gilead Sciences, Inc. today announced Phase II clinical trial results showing that its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat and Truvada (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection maintained a high rate of virologic suppression through 48 weeks, exhibiting antiretroviral activity comparable to that of Atripla(efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).

14 Sep 2010

VAP Cholesterol Test can evaluate Polycystic Ovarian Syndrome

Polycystic Ovarian Syndrome, known as PCOS, is a silent and often mysterious disease that plays havoc with a woman's body and increases the risk of serious illness. There is no single test for diagnosing the illness, but a detailed cholesterol profile called the VAP Cholesterol Test, along with diet, exercise and the right medication, is changing how doctors approach PCOS and is dramatically altering patients' lives for the better.

10 Sep 2010

CaPre drug candidate shows promising result on CRP level reduction

Acasti Pharma Inc., a subsidiary of Neptune Technologies & Bioressources Inc. reports significant results on the effects of its anti-dyslipidemic investigational drug candidate CaPre on C-reactive protein (CRP) levels, a biomarker of CardioVascular Disease risk (CVD) and associated with diabetes and obesity.

3 Sep 2010